Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life

Andrew Blauvelt, Mark Boguniewicz, Patrick M. Brunner, Paula C. Luna, Pinaki Biswas, Marco DiBonaventura, Saleem A. Farooqui, Ricardo Rojo, Michael C. Cameron

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials. Methods: These analyses included data for Investigator’s Global Assessment responder (clear [0] or almost clear [1] with ≥2-grade improvement) and nonresponder patients with moderate-to-severe atopic dermatitis who received abrocitinib (200 mg or 100 mg) or placebo in three abrocitinib monotherapy trials (phase 2 b, NCT02780167; two phase 3, NCT03349060/JADE MONO-1 and NCT03575871/JADE MONO-2). Outcomes measuring skin clearance, itch, and quality of life were evaluated. Results: Both nonresponders (n = 548) and responders (n = 260) treated with abrocitinib had rapid and clinically meaningful improvement in skin clearance, itch, and quality of life compared with placebo. Conclusion: Patients with moderate-to-severe atopic dermatitis treated with abrocitinib who did not achieve an Investigator’s Global Assessment 0/1 response at week 12 still experienced rapid, clinically meaningful improvements across several other validated measures of efficacy and quality of life. ClinicalTrials.gov: NCT02780167, NCT03349060, NCT03575871.

Original languageEnglish
Pages (from-to)2605-2613
Number of pages9
JournalJournal of Dermatological Treatment
Volume33
Issue number5
DOIs
StatePublished - 2022

Keywords

  • Atopic dermatitis
  • eczema
  • pruritus
  • quality of life

Fingerprint

Dive into the research topics of 'Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life'. Together they form a unique fingerprint.

Cite this